Tiziana Life Sciences PLC - biotechnology company - Reports initiation of a collaborative clinical study investigating nasally administered Foralumab either alone or in combination with orally administered dexamethasone in Covid-19 patients in Brazil.
Says teams at Harvard Medical School, Santa Casa de Misericordia de Santos Hospital and at Tiziana are closely collaborating to facilitate initiation of this study in "expedited time frames".
The clinical study will start dosing patients on Tuesday with data expected to be available before the end of 2020.
Current stock price: 128.00 pence
Year-to-date change: up more than three-fold
By Lucy Heming;Â lucyheming@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.